4BASEBIO UK SOCIETAS
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally. The company offers hpDNA, double stranded linear DNA, covalently closed with single strand hairpins at the 5' and 3' ends for viral and non-viral vector applicat… Read more
4BASEBIO UK SOCIETAS (4BB) - Total Liabilities
Latest total liabilities as of June 2025: GBX17.89 Million GBX
Based on the latest financial reports, 4BASEBIO UK SOCIETAS (4BB) has total liabilities worth GBX17.89 Million GBX as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
4BASEBIO UK SOCIETAS - Total Liabilities Trend (2019–2024)
This chart illustrates how 4BASEBIO UK SOCIETAS's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
4BASEBIO UK SOCIETAS Competitors by Total Liabilities
The table below lists competitors of 4BASEBIO UK SOCIETAS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BORYSZEW (BOW.SG)
STU:BOW
|
Germany | €2.24 Billion |
|
FIRST TRACTOR -H-
MU:FTP
|
Germany | €7.01 Billion |
|
Sage Gold Inc
PINK:SGGDF
|
USA | $22.21 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down 4BASEBIO UK SOCIETAS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.94 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 4BASEBIO UK SOCIETAS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 4BASEBIO UK SOCIETAS (2019–2024)
The table below shows the annual total liabilities of 4BASEBIO UK SOCIETAS from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX18.35 Million | +47.79% |
| 2023-12-31 | GBX12.41 Million | +171.70% |
| 2022-12-31 | GBX4.57 Million | +51.95% |
| 2021-12-31 | GBX3.01 Million | +27.90% |
| 2020-12-31 | GBX2.35 Million | -22.79% |
| 2019-12-31 | GBX3.04 Million | -- |